Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter study phase IIb randomized, blind, controlled with Placebo in search of doses to assess efficacy, safety and tolerability of two dose Subcutaneas IPP-201101 more medication of base, versus Placebo more basic medication in patients with Systemic Lupus Erythematosus (SLE).

Next Previous
Trial Profile

Multicenter study phase IIb randomized, blind, controlled with Placebo in search of doses to assess efficacy, safety and tolerability of two dose Subcutaneas IPP-201101 more medication of base, versus Placebo more basic medication in patients with Systemic Lupus Erythematosus (SLE).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Forigerimod (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Sponsors ImmuPharma

    • Most Recent Events

    • 28 Jan 2013 Results have been published in Annals of the Rheumatic Diseases according to an ImmuPharma media release.
    • 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 14 Nov 2012 Status changed from recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top